Benzinga | May 17, 2021 06:57AM EDT

Oppenheimer Downgrades Mirati Therapeutics to Perform, Lowers Price Target to $160

Oppenheimer analyst Jay Olson downgrades Mirati Therapeutics (NASDAQ:MRTX) from Outperform to Perform and lowers the price target from $245 to $160.